MX388461B - Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva. - Google Patents

Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.

Info

Publication number
MX388461B
MX388461B MX2018012739A MX2018012739A MX388461B MX 388461 B MX388461 B MX 388461B MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 388461 B MX388461 B MX 388461B
Authority
MX
Mexico
Prior art keywords
cognitive function
leucine
acetyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2018012739A
Other languages
English (en)
Other versions
MX2018012739A (es
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2018012739A publication Critical patent/MX2018012739A/es
Publication of MX388461B publication Critical patent/MX388461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción está dirigida a acetilleucina o una sal farmacéuticamente aceptable de la misma para usarse en la mejora de la función cognitiva, movilidad o función cognitiva y movilidad en un sujeto, por ejemplo, en un sujeto anciano.
MX2018012739A 2016-04-19 2017-04-19 Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva. MX388461B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (2)

Publication Number Publication Date
MX2018012739A MX2018012739A (es) 2019-06-17
MX388461B true MX388461B (es) 2025-03-20

Family

ID=58633040

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012739A MX388461B (es) 2016-04-19 2017-04-19 Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Country Status (27)

Country Link
US (4) US10905670B2 (es)
EP (2) EP4501406A3 (es)
JP (3) JP7387264B2 (es)
KR (4) KR102413754B1 (es)
CN (2) CN109069463B (es)
AU (2) AU2017252507B2 (es)
BR (1) BR112018071547A2 (es)
CA (1) CA3021155A1 (es)
DK (1) DK3445351T3 (es)
ES (1) ES2994242T3 (es)
FI (1) FI3445351T3 (es)
HR (1) HRP20241552T1 (es)
HU (1) HUE069219T2 (es)
IL (3) IL310508A (es)
LT (1) LT3445351T (es)
MD (1) MD3445351T2 (es)
MX (2) MX388461B (es)
NZ (1) NZ747307A (es)
PL (1) PL3445351T3 (es)
PT (1) PT3445351T (es)
RS (1) RS66142B1 (es)
RU (1) RU2745912C2 (es)
SG (2) SG11201809031XA (es)
SI (1) SI3445351T1 (es)
SM (1) SMT202400459T1 (es)
WO (1) WO2017182802A1 (es)
ZA (1) ZA201806849B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US12145899B2 (en) 2018-12-06 2024-11-19 Intrabio Ltd. Deuterated analogs of acetyl-leucine
KR20210135272A (ko) * 2019-03-02 2021-11-12 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
US12171852B1 (en) 2023-07-18 2024-12-24 Sytheon Ltd Composition and methods for regulating melanogenesis
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
WO2008134844A1 (en) * 2007-05-08 2008-11-13 Multi Formulations Ltd. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
IL310508A (en) * 2016-04-19 2024-03-01 Intrabio Ltd Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
WO2019079536A1 (en) * 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS

Also Published As

Publication number Publication date
JP2019513814A (ja) 2019-05-30
AU2022256077A1 (en) 2022-11-17
CN109069463A (zh) 2018-12-21
KR102791288B1 (ko) 2025-04-03
KR102632670B1 (ko) 2024-02-01
LT3445351T (lt) 2024-11-25
JP2022024058A (ja) 2022-02-08
FI3445351T3 (fi) 2024-11-18
ZA201806849B (en) 2019-07-31
HUE069219T2 (hu) 2025-02-28
MD3445351T2 (ro) 2024-12-31
US20250332133A1 (en) 2025-10-30
IL293266A (en) 2022-07-01
RS66142B1 (sr) 2024-12-31
US20230346732A1 (en) 2023-11-02
EP4501406A2 (en) 2025-02-05
KR20220038814A (ko) 2022-03-29
CN109069463B (zh) 2024-07-23
PL3445351T3 (pl) 2025-01-07
IL310508A (en) 2024-03-01
IL293266B2 (en) 2024-07-01
US12329733B2 (en) 2025-06-17
SMT202400459T1 (it) 2025-01-14
DK3445351T3 (da) 2024-11-04
EP3445351A1 (en) 2019-02-27
RU2018140131A3 (es) 2020-05-14
AU2017252507B2 (en) 2022-07-21
SG11201809031XA (en) 2018-11-29
RU2018140131A (ru) 2020-05-14
IL262379B (en) 2022-07-01
RU2021107001A (ru) 2021-04-12
KR20240018683A (ko) 2024-02-13
KR102413754B1 (ko) 2022-06-27
KR20180134398A (ko) 2018-12-18
CA3021155A1 (en) 2017-10-26
NZ747307A (en) 2025-10-31
US20190083438A1 (en) 2019-03-21
CN118593463A (zh) 2024-09-06
HRP20241552T1 (hr) 2025-01-17
JP2024123087A (ja) 2024-09-10
AU2017252507A1 (en) 2018-11-08
MX2018012739A (es) 2019-06-17
PT3445351T (pt) 2024-11-14
IL262379A (en) 2018-11-29
RU2745912C2 (ru) 2021-04-02
SG10202106190RA (en) 2021-07-29
JP7506046B2 (ja) 2024-06-25
EP3445351B1 (en) 2024-10-16
KR20220093386A (ko) 2022-07-05
US10905670B2 (en) 2021-02-02
JP7387264B2 (ja) 2023-11-28
MX2021014844A (es) 2022-01-18
ES2994242T3 (en) 2025-02-05
EP4501406A3 (en) 2025-03-26
US20210106548A1 (en) 2021-04-15
SI3445351T1 (sl) 2025-04-30
US11998518B2 (en) 2024-06-04
IL293266B1 (en) 2024-03-01
WO2017182802A1 (en) 2017-10-26
BR112018071547A2 (pt) 2019-03-06

Similar Documents

Publication Publication Date Title
MX388461B (es) Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.
IL272089A (en) Compounds, compositions and methods
CL2017003033A1 (es) Dispositivo de monitorización para la aplicación de un fármaco con una pluma de fármaco, con registro, comunicación y alarmas.
TWD172100S (zh) 化粧瓶
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
TWD178500S (zh) 護膚器
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
TWD166031S (zh) 口含物
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
TWD180565S (zh) 塗抹器
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
GB2543709A (en) Pharmaceutical agent
MX2020002485A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
TWD176882S (zh) 按摩裝置
TWD175370S (zh) 按摩器
TWD195659S (zh) Washstand
ES1186059Y (es) Avisador llamador para personas parapléjicas o de movilidad reducida
TWD170668S (zh) 記事板
TWD175621S (zh) 髮梳
TWD197140S (zh) 注射裝置